managed care, healthcare, cancer, melanoma, hospice, ipilimumab, vemurafenib, metastatic, survival rates, end-of-life, healthcare costs, Affordable Care Act, patient-centered, palliative care

Articles by managed care, healthcare, cancer, melanoma, hospice, ipilimumab, vemurafenib, metastatic, survival rates, end-of-life, healthcare costs, Affordable Care Act, patient-centered, palliative care

A study in The American Journal of Managed Care found that longer stays in hospice were associated with longer survival and lower end-of-life costs for patients with metastatic melanoma, a particularly deadly and increasingly common form of cancer.



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo